特应性皮炎流行病学研究方法:全球范围综述
该全球范围综述纳入2023年1月至2024年7月间48个国家的111项基于人群的特应性皮炎(AD)流行病学研究,系统梳理了病例定义、严重度评估、频率指标及关键社会人口学因素。研究发现病例定义高度异质:77.5%研究采用医生诊断、13.5%采用经验证问卷、9.0%采用其他方法;仅17.1%研究报告严重度分布;东南亚和非洲区域研究最少。结论提示AD流行病学研究方法异质性大,限制跨研究比较,未来需统一方法并填补地域空白。
要点
- AD流行病学研究病例定义高度异质,77.5%用医生诊断、13.5%用经验证问卷。
- 仅17.1%研究报告严重度分布,严重度评估报告不足。
- 东南亚和非洲区域AD流行病学研究明显偏少,存在地域空白。
核心结论
- 近期基于人群的AD流行病学研究高度异质,限制跨研究有意义的比较。
- 未来研究应着力解决方法学变异并填补全球疾病负担数据的关键地域空白。
研究设计与样本
- 系统文献检索覆盖2023年1月1日至2024年7月31日共18个月。
- 纳入报告AD患病率和/或发病率的原创性基于人群研究。
- 摘要筛选和数据提取双人盲法完成,按地理区域和年龄组分层的描述性分析以表格和图形呈现。
- 共纳入来自48个国家的111项研究。
主要发现
- AD患病率数据采用多种诊断标准:医生诊断86/111项(77.5%),经验证问卷15/111项(13.5%),其他方法10/111项(9.0%)。
- 病例定义在地理区域间存在 considerable 异质性。
- 研究最少的地区为东南亚(5/120项;4.2%)和非洲(4/120项;3.0%)。
临床怎么用
- 临床解读AD流行病学数据时需注意病例定义和严重度评估方法的差异,避免直接跨研究比较。
- 关注东南亚和非洲等研究稀少地区的AD负担数据缺口。
局限性
- 检索仅覆盖2023年1月至2024年7月共18个月,可能遗漏更早研究。
- 仅纳入报告患病率和/或发病率的原创性基于人群研究,其他类型研究未纳入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) has the highest burden of all skin diseases globally. While numerous systematic reviews and meta-analyses have attempted to estimate the burden of AD at country, regional and global levels, the variability in research methodology often leads to the exclusion of significant portions of data or the aggregation of data representing disparate factors. As a result, improving the understanding of the burden of AD requires a thorough review of the methodologies currently in use. OBJECTIVES: To identify and map the research methodology used in population-based epidemiological studies of AD in terms of the case definitions used, the severity assessment method, measures of frequency and key sociodemographic factors. METHODS: A systematic literature search was conducted, covering an 18-month period from 1 January 2023 to 31 July 2024. Original, population-based studies were included if they reported the prevalence and/or incidence of AD. Abstract screening and data extraction were done in duplicate and in a blinded manner. Descriptive analyses stratified by geographical region and age group are presented in tabular and graphical form. RESULTS: A total of 111 studies from 48 countries were included. Data on AD prevalence used various diagnostic criteria, with studies defining cases by a physician diagnosis (n = 86/111; 77.5%), validated questionnaires (n = 15/111; 13.5%) and other methods (n = 10/111; 9.0%), with considerable heterogeneity between geographical regions. Nineteen studies (17.1%) reported the severity distribution. Geographical regions with the fewest studies on AD were the South-East Asian (n = 5/120; 4.2%) and African (n = 4/120; 3.0%) regions. CONCLUSIONS: Recent population-based epidemiological studies on AD are highly heterogeneous, limiting meaningful comparisons across studies. Future research should aim to address this variability and fill key geographical gaps in the global burden data. Atopic dermatitis (‘AD’ for short) is also known as eczema. It is a common skin condition that causes dry, itchy and inflamed skin. AD affects people of all ages and is one of the most widespread skin conditions in the world. In this study, researchers from several countries worked together to try to understand how studies from around the world have measured how common AD is. To do this, we reviewed 111 studies of AD from 48 different countries. Our goal was to find out what research methods were used in the included studies. Specifically, we wanted to find out how researchers diagnosed and reported cases of AD. We found that different studies used different definitions and tools to diagnose AD. These methods often varied by country or region. Because of this, it can be difficult to compare the frequency of the condition across different parts of the world. In conclusion, our findings highlight the need for more consistent ways to study and report on AD, so researchers, doctors, patients and members of the public can better understand how many people are affected and where help is most needed.
引用
- Chang CY, Chan K, Chen HC, et al. Atopic dermatitis epidemiological research methodology: a global scoping review. Br J Dermatol. 2025. PMID: 40577795. doi:10.1093/bjd/ljaf238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。